Effect of Sinai San decoction on the development of non-alcoholic steatohepatitis in rats

World Journal of Gastroenterology

Volumn 11, Issue 9, 2005, Pages 1392-1395

  Zhang, Qi ^a   Zhao, Yan ^a   Zhang, Deng Ben ^b   Sun, Li Jun ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Traditional Chinese Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; CHOLESTEROL; PLANT MEDICINAL PRODUCT; SINAI SAN DECOCTION; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID DIET; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; RAT; RAT STRAIN; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 15844415299     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i9.1392     Document Type: Article

References (12)

1. Chen QK, Chen HY, Huang KH, Zhong YQ, Han JA, Zhu ZH, Zhou XD. Clinical features and risk factors of patients with fatty liver in Guangzhou area. World J Gastroenterol 2004; 10: 899-902
2. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40: 475-483
3. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004; 35: 196-199
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419
5. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94: 1018-1022
6. Harrison SA, Di Bisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs 2003; 63: 2379-2394
7. Dai N, Zeng M, Li J. Experimental study on inhibitory effect of Chinese herbal compound on hepatocyte cytochrome P450 II E1 expression in rat model of nonalcoholic fatty liver. Zhongguo Zhongxiyi Jiehe Zazhi 2000; 20: 453-455
8. Fan JG, Zeng MD. Classification and diagnostic strategies of nonalcoholic fatty liver diseases. Zhonghua Ganzangbing Zazhi 2003; 11: 127-128
9. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110
10. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-1654
11. Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord 2004; 28: 167-172
12. Zhou CX, Xu Q. Studies on mechanism of Sini San alleviateing liver injury induced by cellular immunological reaction. Zhongguo Zhongyi Jichu Yixue Zazhi 2002; 18: 5-8